Online Only Articles

Efficacy and safety of idelalisib in patients with relapsed, rituximab- and alkylating agent-refractory follicular lymphoma: a subgroup analysis of a phase 2 study

Hospices Civils de Lyon, University Claude Bernard, Pierre Benite, France
Lymphoma Program, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
Department of Hematology/Oncology, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
Departments of Oncology and Hematologic Malignancies, Johns Hopkins University, Baltimore, MD, USA
Department of Internal Medicine III, University Hospital of Ulm, Germany
Division of Hematology, Ohio State University Wexner Medical Center, Columbus, OH, USA
Department of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA
Department of Hematology, Jagiellonian University, Krakow, Poland
Hematologic Malignancies Research Program, Sarah Cannon Research Institute, Nashville, TN, USA
Department of Medicine, Oncology Division, Washington University School of Medicine, St Louis, MO, USA
Division of Hematology/Oncology, Weill Cornell Medical College, NY, USA
Gilead Sciences Inc., Foster City, CA, USA
Gilead Sciences Inc., Foster City, CA, USA
At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA
At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA
At the time of the analyses, Gilead Sciences Inc., Foster City, CA, USA
Institute of Hematology and Oncology, University of Bologna, Italy
Medical Oncology Division, University of Washington School of Medicine, Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Vol. 102 No. 4 (2017): April, 2017 https://doi.org/10.3324/haematol.2016.151738